Empowered Patient Podcast

Jack Hoppin Ph.D. Chief Executive Officer and John Babich Ph.D., President and Chief Scientific Officer, and Co-Founders of Ratio Therapeutics aim to develop and produce best-in-class radiopharmaceuticals. Harnessing the power of radiation by making it into an injectable drug, Ratio is creating a way to find tumor cells anywhere in the body. John explains, "And what we are doing, which is quite unique, is creating a platform of small molecules that can be radiolabeled with a variety of different isotopes. And these radioactive isotopes carry the ability to deliver different types of radiation -- beta particles and alpha particles. They have different toxicities and different lengths, so they travel in the tissue. And by combining the right molecules for the delivery with the right isotope, we're hoping to optimize the ability to control the tumor to basically put it into remission while maintaining a high quality of life. And we do that latter component by making sure that the injected material doesn't go to